Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

摘要

While in RARS-T, JAK2 V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2 V617F mutation status. JAK2 V617F mutation was significantly correlated with lower progression to AML ( p <.0011) and better overall survival (OS, p =.011). OS difference persisted after matching on age, sex, IPSS and % marrow blast ( p =.031). Thus, in MDS other than RARS-T, JAK2 V617F mutation may be associated with favorable outcome.